Intech Investment Management Reduces Stake in Bristol Myers Squibb

Institutional investor trims position in pharmaceutical giant

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Intech Investment Management LLC, an institutional investor, lowered its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 5.6% during the third quarter. The firm now owns 163,454 shares of the biopharmaceutical company's stock, valued at $7.37 million.

Why it matters

Bristol Myers Squibb is a major pharmaceutical company with a focus on oncology, hematology, immunology, and cardiovascular treatments. Changes in institutional ownership can signal shifts in market sentiment around the company and its prospects.

The details

Intech Investment Management sold 9,655 shares of Bristol Myers Squibb during the third quarter, reducing its total position to 163,454 shares. The firm cited unspecified reasons for the stake reduction. Bristol Myers Squibb's stock has risen over the past year as the company has advanced its pipeline of cancer and immune-mediated disease treatments.

  • Intech Investment Management reduced its Bristol Myers Squibb stake during the 3rd quarter of 2026.

The players

Intech Investment Management LLC

An institutional investment management firm that has reduced its position in Bristol Myers Squibb.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, with a strong emphasis on cancer and immune-mediated conditions.

Got photos? Submit your photos here. ›

The takeaway

This reduction in institutional ownership of Bristol Myers Squibb shares suggests some investors may be taking a more cautious view of the company's prospects, even as the pharmaceutical firm continues to advance its pipeline of innovative treatments.